USA Archives

News and Trends 9 Aug 2022

Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment

A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc that will give GSK the option to co-develop and commercialize an antibody drug conjugate (ADC). The ADC called XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Anna […]

August 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics

Positive topline results from a phase 3 trial looking at the effect of a drug to treat schizophrenia were announced today (August 8). Karuna Therapeutics Inc, the founded entity of PureTech Health plc, said results from the EMERGENT-2 trial evaluating the efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults met its primary endpoint and […]

August 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Dallas College gets $8.8M grant to grow biotech workforce in North Texas

Dallas College has been awarded a U.S. Economic Development Administration grant to help underserved communities access living-wage jobs in biotechnology. The college noted biotech is a sector poised to grow exponentially with the need for additional highly skilled employees in North Texas, according to the latest labor market intelligence. With approximately $8.8 million in funds […]

August 8, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 8 Aug 2022

HUTCHMED drug in colorectal cancer trial meets primary endpoint

A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint of overall survival (OS) in patients with the disease. China’s HUTCHMED Limited announced today (August 8) that the phase 3 FRESCO-2 trial investigating the use of fruquintinib had met all secondary endpoints too. The […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Allogenic immune cell therapies to be developed as three groups join forces

Three entities have joined forces to develop allogenic immune cell therapies based on a platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). ElevateBio LLC is a technology-driven company focused on powering transformative cell and gene therapies. It announced recently (August 5) that it has formed a yet-to-be-named company co-founded by […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the US Food and Drug Administration (FDA) and a study can now go ahead. Neurocrine Biosciences received the news and informed its partner Sosei Group Corporation. The approval of the study of NBI-1117568 has triggered a $30 million payment to Sosei. […]

August 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […]

August 5, 2022

News and Trends 5 Aug 2022

Abivax has approval granted to enroll ulcerative colitis patients in two studies

Patients with moderate to severe ulcerative colitis (UC) can now be enrolled onto two phase 3 induction studies for a biotech company’s lead candidate drug. France-based Abivax SA is a phase 3 clinical stage biotech company that focuses on developing therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer. […]

August 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Immunis closes $10M financing round

Immunis Inc., a private U.S. biotech company developing a novel treatment for age and disease-related immune decline, has closed a $10 million series A first closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded phase 1/2a clinical […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health. The recombinant enzyme is a double-mutant cocaine esterase 200 mg intravenous (IV) solution and treats cocaine intoxication, which refers to the state of when cocaine […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

U.S. biotech company Novavax, Inc., has started its phase 2b/3 Hummingbird global clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series. “We […]

August 4, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment

Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics

Dallas College gets $8.8M grant to grow biotech workforce in North Texas

HUTCHMED drug in colorectal cancer trial meets primary endpoint

Allogenic immune cell therapies to be developed as three groups join forces

Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

Abivax has approval granted to enroll ulcerative colitis patients in two studies

Immunis closes $10M financing round

First of its kind drug, to reverse effects of cocaine intoxication, awarded grant

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!